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ABSTRACT
The glycosylated protein vasorin physically interacts with the transforming 
growth factor-beta1 (TGF-β1) and functionally attenuates its fibrogenic signaling in 
the vascular smooth muscle cells (VSMCs) of the arterial wall. Angiotensin II (Ang II) 
amplifies TGF-β1 activation in the VSMCs of the arterial wall with aging. In this study, 
we hypothesized that a reduced expression of the protein vasorin plays a contributory 
role in magnifying Ang II-associated fibrogenic signaling in the VSMCs of the arterial 
wall with aging. The current study shows that vasorin mRNA and protein expression 
were significantly decreased both in aortic wall and VSMCs from old (30 mo) vs. 
young (8 mo) FXBN rats. Exposing young VSMCs to Ang II reduced vasorin protein 
expression to the levels of old untreated cells while treating old VSMCs with the Ang 
II type AT1 receptor antagonist Losartan upregulated vasorin protein expression 
up to the levels of young. The physical interaction between vasorin and TGF-β1 was 
significantly decreased in old vs. young VSMCs. Further, exposing young VSMCs to 
Ang II increased the levels of matrix metalloproteinase type II (MMP-2) activation 
and TGF-β1 downstream molecules p-SMAD-2/3 and collagen type I production up 
to the levels of old untreated VSMCs, and these effects were substantially inhibited 
by overexpressing vasorin. Administration of Ang II to young rats (8 mo) for 28 days 
via an osmotic minipump markedly reduced the expression of vasorin. Importantly, 
vasorin protein was effectively cleaved by activated MMP-2 both in vitro and in vivo. 
Administration of the MMP inhibitor, PD 166793, for 6 mo to young adult (18 mo) via 
a daily gavage markedly increased levels of vasorin in the aortic wall. Thus, reduced 
vasorin amplifies Ang II profibrotic signaling via an activation of MMP-2 in VSMCs 
within the aging arterial wall.
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INTRODUCTION
Collagen deposition and infiltration of medial 
vascular smooth muscle cells (VSMCs) into the intima 
are microscopic characteristics of arterial aging and 
angioplasty after injury [1–3]. Consequent collagen build-
up and intimal VSMCs cellularity result from increased 
angiotensin II (Ang II) signaling, activation of matrix 
metalloproteinase type II (MMP-2), and transforming 
growth factor-beta 1 (TGF-β1) in the aged arterial wall 
[4, 5].
The Ang II peptide and its receptor AT1 are 
upregulated in arterial walls with aging, and this 
phenomenon is closely associated with an enhancement 
of both sympathetic nerve activity and cyclic 
mechanical stress [1]. The sympathetic neurotransmitter 
norepinephrine and its alpha-receptor expression are 
upregulated in the arterial walls with aging [6–10], 
contributing to an increase of the Ang II protein abundance 
and upregulation of the AT1 receptor [4]. The age-
associated elevation of pulse pressure increases the arterial 
cyclic mechanical strain force and subsequently promotes 
the expression of both Ang II protein and AT1 receptor 
signaling [11–13]. Importantly, Ang II is also a potent 
activator of both TGF-β1 and MMP-2 [5].
Vasorin, also known as anti-tissue necrosis factor 
alpha (TNFα)-induced apoptosis (ATiA) or slit-like 2 
(slit2) protein, is a classic type I membrane protein, 
including 10 tandem arrays of a leucine-rich repeat motif, 
an epidermal growth factor-like motif, and a fibronectin 
type III-like motif at the extracellular domain, which is 
highly glycosylated in vivo [2, 14, 15]. This extracellular 
cell surface glycoprotein, predominantly derived from 
VSMCs, is a substrate of MMP-2 and is developmentally 
regulated [16–18]. Notably, vasorin, by physically binding 
to TGF-β1, functionally limits TGF-β1 downstream 
signaling such as SMAD-2/3 phosphorylation and collagen 
production via a blockade of access to its receptor, TGF β 
receptor type I & II, on the surface of VSMCs [2]. During 
an acute injury, the amount of vasorin decreases while the 
amount of TGF-β1 increases, contributing to an imbalance 
of the vasorin / TGF-β1extracellular protein ratio, which 
greatly modulates arterial fibrotic remodeling [2, 15].
In the current study, we hypothesize that a reduced 
expression of vasorin protein, due to its cleavage by 
MMP-2, amplifies the Ang II/ TGF-β1 fibrogenic 
signaling in the arterial wall with aging. Indeed, the 
present in vivo and in vitro studies, for the first time, 
documents that aging decreases the expression of vasorin, 
mainly due to an increase in its cleavage mediated by 
MMP-2, which consequently amplifies Ang II/TGF-β1 
fibrogenic signaling and VSMC invasiveness with 
advancing age. In contrast, the upregulation of vasorin 
protein, as well as prevention of its cleavage, substantially 
delays fibrogenesis and VSMC invasiveness in the arterial 
wall with aging. Thus, vasorin appears to be a potent 
novel modulator of Ang II signaling and is a molecular 
target to retard the fibroplasia of arterial aging.
RESULTS
Vasorin expression in arterial walls and VSMCs
To determine the effect of aging on the expression of 
vasorin in the arterial wall or VSMCs, thoracic aortae were 
harvested from 8-mo-old young (8 mo) and 30-month-old 
(30 mo) FXBN rats and VSMCs isolated.
RT-PCR showed that vasorin mRNA levels were 
markedly decreased in old vs. young rat aortae (Figure 
1A). Immunohistostaining of rat aortic walls demonstrated 
that vasorin protein signal was decreased (~3-fold) in 
old vs. young rat aortae (Figure 1B). Western blotting 
of homogenous rat aortic protein further demonstrated 
that the expression levels of the vasorin protein were 
significantly downregulated in old vs. young rats 
(Figure 1C).
Similarly, vasorin mRNA abundance was 
significantly decreased in cultured VSMCs isolated from 
old vs. young rat aortae (Figure 2A); likewise, vasorin 
immunostaining signal was diminished in old vs. young 
cells (Figure 2B); and vasorin protein levels determined 
by immunoblotting were also significantly decreased in 
old vs. young rat VSMCs (Figure 2C).
Vasorin expression and Ang II signaling in 
arterial walls or VSMCs
Ang II increases activation of MMP-2 in the arterial 
wall and VSMCs with aging [4]. Vasorin is a substrate of 
activated MMP-2 [17, 18]. Therefore, we next explored 
the relationships between increased Ang II signaling, 
vasorin expression and its cleavage in the arterial wall or 
cultured VSMCs with aging.
Arterial specimens from a prior Ang II infusion 
experiment were utilized in the following data set [4]. 
We used immunohistostaining and demonstrated that the 
administration of Ang II to 8-mo-old young rats (8 mo) 
for 1 month (Ang II infusion) markedly decreased the 
expression of vasorin protein in the aortic wall compared 
to vehicle animals (control) (Figure 3A), which is 
consistent with the increase of activated MMP-2 described 
previously [4]. The exposure of young VSMCs to Ang 
II dose-dependently reduced the expression of vasorin 
protein down to levels resembling that of untreated old 
cell (Figure 3B). Importantly, this effect was abolished by 
the Ang II AT1 receptor antagonist, Losartan (Los) (Figure 
3B). Furthermore, treating old VSMCs with Los dose-
dependently increased the expression of vasorin protein 
up to the levels observed in untreated young cells (Figure 
3B). Unexpectedly, the treatment of VSMCs with Ang 
II did not significantly alter the mRNA levels of vasorin 
as observed for its protein (Figure 3C). These findings 
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strongly suggest that the levels of vasorin protein may be 
modified by Ang II signaling-associated post-translational 
modifications, such as the MMP-2-mediating its cleavage.
Indeed, the current in vitro and in vivo observations 
indicated that activated MMP-2 has a high capacity 
to cleave both recombinant human and monkey aortic 
vasorin protein, which were evidently blocked by the 
MMP inhibitor, GM 6001 (Figure 4A & 4B). Again, we 
used specimens from a prior study [5], demonstrating 
that 6-months administration of the MMP inhibitor, 
PD 166793, to 18-mo-old young adult rats, markedly 
increased the level of vasorin (~3-fold) in the aortic wall 
(MMP inhibitor) compared to vehicle animals (control) 
(Figure 4C). Importantly, Ang II or aging induced decrease 
Figure 1: Vasorin expression decreases in arterial walls with aging. (A) Aortic vasorin mRNA determined by RT-PCR. Data 
shown as mean ± SEM (n= 4 rats/group). T-test, ***= p<0.001. (B) Immunohistostaining of vasorin (brown color, 400X) in aortic walls. 
All micrographs were taken at the same exposure time. Data of staining vasorin area/arterial area ratio (%, lower panel) shown as mean ± 
SEM (n= 4 rats/group). T-test, * =p<0.05. L=lumen; M=media. Bar scale, 10 μm. (C) Representative western blots of aortic vasorin. Data 
(right panel) shown as mean ± SEM (n= 3 rats/group). Each column represents a normalized ratio (fold-changes) to tubulin and to 8 mo. 
T-test, *=p<0.05.
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of vasorin protein abundance was restored by MMP 
inhibitor, GM6001, treatment (Supplementary Figure 
2). In addition, we tested whether a well-known vasorin 
cleavage proteinase, the disintegrin metalloproteinase 
Figure 2: Vasorin expression decreases in VSMCs with aging. (A) VSMC vasorinm RNA determined by RT-PCR. Data shown 
as mean ± SEM (n= 6 rats/group). T-test, *=p<0.05. (B) Representative immunohistostaining (X400) of vasorin (green) and nuclei (blue) 
in VSMCs captured by confocal microscopy. All micrographs were taken at the same exposure time. Bar scale, 20 μm. (C) Representative 
western blots of VSMC vasorin. Data (right panel) shown as mean ± SEM (n=3 independent experiments from n=3 rats/group). Each 
column represents a normalized ratio (fold-change) to tubulin and to 8 mo. T-test, *=p<0.05.
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17 (ADM17), may also play a contributory role in the 
decrease of vasorin protein in the arterial wall with 
aging [16, 19–22]. Unexpectedly, the abundance of 
ADAM17 protein was unaltered in VSMCs with aging 
(Supplementary Figure 1).
Thus, the current in vivo and in vitro studies 
demonstrate the reduced levels of vasorin in aging VSMCs 
and arterial wall are mainly due to its cleavage by MMP-2.
The physical interaction of vasorin with TGF-β1 
acts like an AT1 antagonist and modifies Ang II 
downstream fibrogenic signaling
It is known that vasorin effectively traps TGF-β1 
protein and blocks its signaling in VSMCs [2]. In the 
current study, co-immunoprecipitation experiments 
demonstrated that the abundance of vasorin bound TGF-β1 
significantly declined in old VSMCs when compared 
to those from young cells (Figure 5A). Accordingly, 
dual immuno-labeling indicated that the extent of co-
localization of vasorin and TGF-β1 markedly declined in 
old VSMCs compared to young cells (Figure 5B).
To determine whether Ang II, via AT1 signaling, 
affects the activation of both MMP-2 and TGF-β1 in 
VSMCs with aging, young VSMCs were treated with Ang 
II and results showed that Ang II significantly elevated 
the levels of both activated MMP-2 and activated TGF-β1, 
resembling those of old untreated cells. However, these 
effects were substantially diminished by AT1 antagonist, 
Los (Figure 6A & 6B).
Figure 3: Age decreases vasorin expression in aortic wall or VSMCs via Ang II signaling. (A) Representative 
immunohistostaining of vasorin (brown, X400) of carotid arteries harvested from young rats infused with either Ang II (Ang II infusion) 
or vehicle saline animals (control). All micrographs were taken at the same exposure time. Data of relative vasorin staining area (%) (right 
panel) shown as mean ± SEM (n= 5 rats/group). T-test, *=p<0.05. L=lumen; M=media. Bar scale, 10 μm. (B) Representative western blots 
of VSMC vasorin. Cells have been pre-treated for 1 hour with Los, and then exposed for 24 hours to a medium containing both Ang II and 
Los. Data (right panel) shown as mean ± SEM (n=4 independent experiments from n=4 rats/group). One-way ANOVA followed Bonferroni 
post hoc test, *p<0.05, **=p<0.01; and ***=p<0.001. Ang II = Angiotensin II; Los=Losartan.; and M=Molar concentration. (C) VSMC 
vasorin mRNA determined by RT-PCR. Cells have been treated for 24 hours in medium containing Ang II. Data shown as mean ± SEM (n= 
6 rats/group). T-test, n.s = no significant.
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Next, we wanted to investigate whether the interplay 
between vasorin and TGF-β1, like Los, block the signaling 
of Ang II / TGF-β1 in VSMCs with aging. To this end, 
vasorin was overexpressed in both young and old VSMCs 
by using a plasmid containing the human vasorin cDNA 
(a representative experiment of VSMCs overexpressing 
vasorin is reported in Supplementary Figure 3). Indeed, 
treating young VSMCs with Ang II increased the levels 
of TGF-β1 downstream molecules p-SMAD-2/3 and Col 
I, up to the levels of untreated old VSMCs, and this set of 
effects were abolished by the overexpression of vasorin 
(Figure 7A & 7B).
Finally, we ran a set of experiments to further 
investigate whether the above effects are linked to variations 
of the active TGF-β1 levels, or to the alleviation of its 
receptor signaling. Results shown that treating old VSMCs 
with the recombinant human vasorin protein did not affect 
the level of activated TGF-β1 (Figure 8, top panel), but 
markedly blocked the TGF-β1 downstream signals dose-
dependently inhibiting the expression of p-SMAD/-2/3, 
Coll I, and activated MMP-2 (Figure 8). These findings 
suggest that vasorin alleviates the fibrogenic signaling in 
VSMCs by limiting the TGF receptor downstream signaling 
independently from the levels of activated TGF-β1.
Figure 4: Vasorin is an MMP-2 substrate. (A) Representative western blots of vasorin showing that the purified human vasorin 
was cleaved by the activated MMP-2. Recombinant human vasorin (400 ng/ml) was incubated in a developing buffer containing activated 
MMP-2 (50 nM) with or without an MMP inhibitor GM6001 (20 nM) for 24 hours at 37°C (n= 4 independent experiments). Western blots 
were probed with vasorin antibody, which detected the intact vasorin (~100 kDa) and a soluble fragment (~75 kDa). (B) Representative 
western blots of vasorin showing that the monkey aortic homogenate containing vasorin was cleaved step-wisely by MMP-2. Monkey 
aortic lysates (25 μg/ml) were incubated in a developing buffer containing activated MMP-2 (50 nM) with or without an MMP inhibitor 
GM6001 (20 nM) for 24 hours at 37°C (n= 3 independent experiments from 3 monkeys). Western blots were probed with vasorin antibody, 
which detected the intact vasorin (~100 kDa) and three soluble fragments (~75 kDa, 50 kDa, and 37 kDa) showing intact arterial vasorin 
was processed by activated MMP-2. (C) Representative immunohistostaining of vasorin (brown, X400) of aortae harvested from adult 
young rats administrated with either the MMP inhibitor PD166793 (MMP inhibitor) or vehicle 0.1% dimethyl sulfoxide animals (control). 
All micrographs were taken at the same exposure time. Data of relative vasorin staining area (%) (right panel) shown as mean ± SEM (n= 
5 rats/group). T-test, **=p<0.01. L=lumen; M=media. Bar scale, 10 μm.
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Taken together, the current findings further prove 
that vasorin directly binds to TGF-β1 and modulates its 
signaling in VSMCs with aging.
Vasorin, Ang II associated MMP-2 activation, 
and VSMC invasion
MMP-2 activation and its subsequent driving of 
VSMCs invasion exert an important role in relaying the 
signaling of Ang II in adverse arterial remodeling. Here, 
we sought to demonstrate that vasorin overexpression 
can affect Ang II associated MMP-2 activation and 
VSMC invasion. Indeed, exposure of young VSMCs 
to Ang II increased the levels of activated MMP-2 to 
those of untreated old VSMCs, and these effects were 
substantially inhibited by the overexpressing of vasorin 
(Figure 9A) and by the treatment with the recombinant 
human vasorin protein (Figure 9B). Moreover, 
old VSMCs that were transfected with the vasorin 
plasmid showed reduced levels of MMP-2 activation, 
comparable with levels of untreated young VSMCs 
(Figure 9A).
Together these results support the hypothesis that 
vasorin, like Ang II blockade, modifies Ang II associated 
MMP-2 activation in VSMCs with aging.
Finally, we wanted to test whether vasorin inhibits 
the Ang II associated VSMC invasion. Indeed, young Ang 
II-treated VSMCs showed a significant increase in their 
invasive capacity (similar to that of old cells), which was 
abolished by both vasorin overexpression and recombinant 
human vasorin protein treatment (Figure 10A and 10B).
Taken together, these results indicate that vasorin 
may modify Ang II associated MMP-2 activation and 
VSMC invasion.
DISCUSSION
The present study, for the first time, demonstrate 
that a reduction in the glycoprotein vasorin, coincides with 
the increases in Ang II signaling, MMP-2 and TGF-β1 
activation, in the arterial wall or VSMCs via AT1 signaling 
with advancing age (Figure 11). The reduced vasorin 
protein in the aging arterial wall or cells is due mainly to 
an increase of vasorin cleavage by MMP-2. A reduction in 
Figure 5: The Interaction of vasorin and TGF-β1 in VSMCs with aging. (A) Co-immunoprecipitation of TGF-β1 and vasorin 
in VSMCs. Cell lysates were immunoprecipitated with an anti- TGF-β1 antibody and then the western blotting against both vasorin and 
TGF-β1 were performed. Data (right panel) shown as mean ± SEM (n= 4 independent experiments/group). Each column represents a 
normalized ratio (fold-changes) to tubulin and to 8 mo. T-test, *=p<0.05. (B) Dual labelling (X630) of vasorin (green) and TGF-β1 (red) 
in VSMCs. All micrographs were taken at the same exposure time. Data of the relative colocalized area (%, right panel) shown as mean ± 
SEM (n= 4 independent experiments/group). T-test, *=p<0.05. T-test, ***=p<0.001. Bar scale, 10 μm.
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the vasorin protein amplifies the Ang II signaling, MMP-
2, and TGF-β1 activation in the arterial wall or cells with 
aging (Figure 11). Thus, preserving an effective level 
of intact vasorin is a novel molecular target to maintain 
VSMC quiescence and collagen homeostasis in the arterial 
wall that accompanies advancing age.
The decrease of vasorin in the arterial wall or 
VSMCs with aging is mediated by activation of the Ang II/
AT1/MMP-2 signaling cascade. The current study, for the 
first-time, documents that similar to the aging process, Ang 
II decreases the expression of vasorin protein in the arterial 
wall or VSMCs via an activation of the AT1 receptor; 
in contrast, a blockade of the AT1 receptor signaling 
increases the expression of vasorin in VSMCs. Ang II does 
not markedly alter the mRNA levels of vasorin in VSMCs. 
These findings suggest that the age associated decreases 
in vasorin protein abundance is due at least partially to 
its post-translational modifications through cleavage. 
Prior studies and current findings suggest that the vasorin 
protein is susceptible to be degraded by activated MMP-2 
[17, 18]. It is well-known that Ang II or aging increases 
the activation of MMP-2 in the arterial wall, arterial rings, 
and VSMCs [20–23]. The current findings show that 
the activated MMP-2 substantially degrades the vasorin 
protein in vitro and in vivo. Importantly, the prevention 
of vasorin cleavage by the MMP inhibitor PD166793, 
is linked with the retardation of adverse age-associated 
arterial fibrogenic remodeling [24]. Notably, the current 
study indicates that the aging process itself does not alter 
the expression of the ADAM17 protein in VSMCs, which 
is known to cleave vasorin in vivo and in vitro [16, 19–22], 
thus excluding this proteinase from the current analysis of 
aging-related phenomena. Taken together these findings 
suggest that MMP-2 plays an important contributory 
role in decreasing vasorin protein in the arterial wall or 
VSMCs with advancing age.
Vasorin, interacting with TGF-β1, in a manner 
that resembles the Ang II receptor antagonist, decreases 
Figure 6: Ang II, MMP-2 and TGF-β1 activation in VSMCs. (A) Representative zymogram of the medium from early passage 
cultured VSMCs treated with either Angiotensin II (Ang II) Losartan (Los) (upper panel). Cells have been pre-treated for 1 hour with 
Los (5X10-6 M), and then exposed for 24 hours to a medium containing both Ang II (5X10-6 M) and Los (5X10-6 M). Data (lower panel) 
shown as mean ± SEM (n=4 independent/group). One-way ANOVA followed Bonferroni post hoc test, *=p<0.05, and **=p<0.01. (B) 
Representative western blots of TGF-β1 from lysates from early passage cultured VSMCs treated with either Ang II or Los (upper panel). 
Cells have been pre-treated for 1 hour with Losartan (5X10-6 M), and then exposed for 24 hours to a medium containing both Ang II (5X10-6 
M) and Los (5X10-6 M). Data (lower panel) shown as mean ± SEM (n=4 independent/group). Each column represents a normalized ratio 
(fold-changes) to tubulin and to untreated 8 mo VSMCs. One-way ANOVA followed Bonferroni post hoc test, *=p<0.05, and **=p<0.01.
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Figure 7: Age increases TGF-β1 downstream profibrotic molecules in VSMCs mediated by over-expressing vasorin. (A) 
Representative western blots for p-SMAD-2/3 and total SMAD-2/3 of VSMCs transfected with either control DsRed or DsRed containing 
human vasorin cDNA (DsRed HV) plasmid and treated with or without Ang II (5X10-6 M) for 24 hours. Data (right panel) shown as mean 
± SEM (n=6 independent/group). Each column represents a normalized ratio (fold-changes) to tubulin and to 8 mo + DsRed. One-way 
ANOVA followed Bonferroni post hoc test, *=p<0.05, and **=p<0.01. (B) Representative western blots for collagen Type I (Col I) of 
VSMCs transfected with either control DsRed or DsRed containing human vasorin cDNA (DsRed HV) plasmid and treated with or without 
Ang II (5X10-6 M) for 24 hours. Data (right panel) shown as mean ± SEM (n=6 independent/group). Each column represents a normalized 
ratio (fold-change) to tublin and to 8 mo + DsRed. One-way ANOVA followed Bonferroni post hoc test, *=p<0.05, and **=p<0.01.
Figure 8: TGF-β1 downstream profibrotic effects in old VSMCs regulated by recombinant human vasorin proteins. 
(A) Representative western blots of TGF-β1, p-SMAD-2/3, SMAD-2/3, Coll I, β-actin, and Zymogram from lysates of early passage 
cultured VSMCs treated with or without recombinant human vasorin proteins at the indicated doses. (B) Data shown as mean ± SEM (n=3 
independent/group). Each column represents a normalized ratio (fold-change) to β-actin and to untreated control (0). One-way ANOVA 
followed Bonferroni post hoc test, *=p<0.05, **=p<0.01 and ***=p<0.001.
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Figure 9: The Ang II associated MMP-2 activation with aging mediated by vasorin. (A) Representative zymogram from 
VSMCs transfected with either control DsRed or DsRed containing human vasorin cDNA (DsRed HV) plasmid and treated with or without 
Ang II (5X10-6M) for 24 hours. Data (right panel) shown as mean ± SEM (n=4 independent experiments/group). One-way ANOVA 
followed Bonferroni post hoc test, *=p<0.05 and **=p<0.01. STD=standard: activated MMP2 protein. (B) Representative zymogram from 
VSMCs treated with Ang II (5X10-6M) with or without recombinant human vasorin protein (100 ng/ml). Data (right panel) shown as mean 
± SEM (n=3 independent experiments/group). One-way ANOVA followed Bonferroni post hoc test, ***=p<0.001.
Figure 10: Vasorin decreases both Ang II- and aging-associated phenotypic shift of VSMCs into invasiveness. (A) 
Invasion assay of VSMCs transfected with either control DsRed or DsRed containing human vasorin cDNA (DsRed HV) plasmid and 
treated with or without Ang II (5X10-6 M) for 4 hours using modified Boyden chamber. Data shown as mean ± SEM (n=3 independent 
experiments/group). One-way ANOVA followed Bonferroni post hoc test, **=p<0.01 and **=p<0.001. HPF= high power field. (B) Invasion 
assay of VSMCs treated with without Ang II and human recombinant vasorin protein for 4 hours using modified Boyden chamber. Data 
shown as mean ± SEM (n=3 independent experiments/group). One-way ANOVA followed Bonferroni post hoc test, *=p<0.5 and **p<0.001. 
HPF= high power field.
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pro-fibrogenic effects in aging VSMCs. Indeed, vasorin 
strongly binds to TGF-β1, and subsequently blocks TGF-β 
receptors type I and II activation and their downstream 
signals [20, 25]. Overexpression of vasorin in old VSMCs 
decreases TGF-β1 downstream signaling (p-SMAD-2/3 
and Col I production) to levels resembling those achieved 
by Losartan-treated old cells. Further, in young VSMCs, 
overexpression of vasorin counteracts the Ang II-induced 
increases in TGF-β1 signaling (p-SMAD-2/3 and Col I 
production). Importantly, old VSMCs treated with the 
vasorin protein, substantially blocked the expression of 
TGF-β1 downstream molecules such as p-SMAD-2/3, 
although the levels of activated TGF-β1 remained constant, 
further supporting the hypothesis that vasorin alleviate 
TGF-β1 signaling by blocking its access to the TGF-β 
receptors. These findings also further support the novel 
concept that vasorin physically traps TGF-β1, mimicking 
the AT1 antagonist Los, thus mitigating Ang II associated 
fibrotic effects in the arterial wall or VSMCs with aging.
Increased intimal VSMCs infiltration is a key 
cellular event for arterial remodeling with aging and is 
closely associated with the activation of Ang II associated 
MMP-2 [4, 26]. Ang II increases MMP-2 activation 
and promotes a rapid transition from a contractile 
differentiated phenotype to a synthetic dedifferentiated 
invasive phenotype of VSMCs [4]. Vasorin overexpression 
or protein treatment inhibits Ang II associated activation 
of MMP-2 and the invasiveness of VSMCs with aging. 
These findings reveal that vasorin modulates aging/Ang II 
associated activation of MMP-2 and VSMCs invasiveness.
Growing evidence indicates that vasorin is involved in 
the modulation of adverse arterial remodeling such as arterial 
Figure 11: Schematic diagram showing the Ang II-associated TGF-β1 signaling affected by vasorin cleavage due to 
MMP-2 activation in VSMCs or arterial walls with aging. Ang II=angiotensin II, Los=losartan, MMP-2=matrix metalloproteinase 
type II, TGF-β1=tissue transforming growth factor-beta1, VSMC=vascular smooth muscle cells.
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restenosis and calcification [2, 3, 27]. Local vasorin protein 
levels are inversely related to the degree of arterial restenosis 
[3]. Reduction of circulating vasorin is closely correlated 
with the incidence and severity of aortic valve calcification 
in humans [27]. Conversely, overexpression of vasorin 
directly alleviates neointima thickening [2]. Administration 
of a novel immunosuppressant FK778 or inhibition of miR-
146a significantly reduces coronary restenosis and arterial 
neointima formation, a phenomena that is accompanied by 
the upregulation of vasorin levels [23, 28–32].
Taken together, these data indicate that vasorin is 
not only involved in acute arterial injury, but also in age-
associated vascular remodeling through the modulation of 
the Ang II signaling cascade. Vasorin levels are reduced by 
age-associated increases in Ang II due mainly to its cleavage 
by MMP-2. A reduction in vasorin magnifies the Ang II 
mediated increase in the TGF-β1 signaling cascade and 
invasion of VSMCs with aging. Thus, maintaining the levels 
of arterial vasorin is a potential novel therapeutic platform 
to prevent age-related adverse vascular remodeling.
MATERIALS AND METHODS
Experimental animals
All procedures were performed per protocols 
approved by the National Institute on Aging (NIA) in 
accordance with the National Institute of Health (NIH) 
Animal Care and Use Committee. Eight-month-old (8mo, 
young) and 30-month-old (30mo, old) male Fisher 344 
crossbred Brown Norway (FXBN) rats were obtained 
from National Institution on Aging Aged Rodent Colonies. 
Animals were sacrificed and thoracic aortae were 
harvested as previously described [33]. Aortic tissues were 
paraffin embedded and sectioned for histology study and 
their protein and ribonucleic acid (RNA) were extracted 
for western blotting and Real-time polymerase chain 
reaction (RT-PCR) analysis.
VSMCs in culture
VSMCs were isolated from both young and old 
FXBN rat aortae as previously described [34]. Cells were 
sub-cultured (passage 3-6) in modified DMEM with 10% 
fetal bovine serum (FBS). After serum removal for 24 
hours, cells were treated with Ang II (Sigma) or Losartan 
(Toronto Research Chemicals, E96000) or human vasorin 
protein (Sino Biological Inc., Beijing, China) or vehicle 
in 2.5% FBS for 24 hours. Other treatments are reported 
in the figure legends. Cultured VSMCs were lysed for 
protein and RNA isolation for Western Blot and q-RT-PCR 
analysis.
Immunostaining, immunofluorescence staining, 
and morphometric analysis
Staining of aortic walls and VSMCs were 
performed as described in previous studies [35]. For 
immnocytostaining, VSMC were fixed and processed 
for immunofluorescence with anti-vasorin and anti-
TGF-β1 antibodies. Images were taken using the confocal 
espectral Olympus FV1000 (Olympus, Center Valley, 
PA, USA). Details of primary antibodies used are listed 
in Table 1. The ratios of target immunohistochemical 
or immunofluorescence staining positive area to the 
total tissue or cell area were determined via computer-
imaging program according to the instruction provided 
by manufacture utilizing light microscopy (MetaMorph 
Imaging System, Universal Imaging Corp., PA).
Real-time quantitative reverse transcription 
PCR
Real-Time Quantitative Reverse Transcription 
PCR (q-RT-PCR) of rat aortic vasorin was performed 
according to modified methods as previously 
described [26, 34]. Vasorin primer information: CTCA 
Table 1: Primary Antibodies
Antibody Specie Titer Blotting Titer Staining Source
α-SMA M 1:1000 Sigma, MO
ADAM17 R 1:1000 Abcam, MA
β-actin M 1:5000 Sigma, MO
Col I R 1:500 1:80 Santa Cruz, CA
GAPDH M 1:4000 1:50 Sigma, MO
SMAD 2/3 R 1:200 1:50 Santa Cruz, CA
TGF-β1 R 1:500 1:100 Santa Cruz, CA
Tubulin M 1:1000 Santa Cruz, CA
Vasorin R 1:500 1:50 Santa Cruz, CA
R=rabbit; and M=mouse.
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GCCACAGTCGTCTCC for the forward; and GA 
TGGGCAGCTCTGTACTCC for the reverse. In brief, 
RNA was extracted from frozen aortae or cultured 
VSMCs using Trizol reagent (Thermo Fisher Scientific, 
Halethorpe, MD). Real-time PCR was performed per the 
SYBRGreen PCR protocol (Applied Biosystems, Foster 
City CA). Each sample was tested in quadruplicate. 
Data are expressed using the formula: quantity=10–(Ct-Y 
intercept)/slope value) where Ct represents the threshold cycle 
value.
Western blotting
Western blots of aortic tissue protein, and cultured 
VSMC protein were performed as previously described 
[26, 34, 35]. In brief, the total protein was quantified 
using the Bio-Rad (Hercules, CA, USA) according to 
the manufacturer’s instructions. In breif, 10 μg of total 
proteins were run on 4-12% NuPAGE gels (Thermo 
Fisher Scientific, Halethorpe, MD), transferred to a PVDF 
membrane and immunoblotted with antibodies against 
vasorin, ADAM17, p-SMAD-2/3, SMAD-2/3, Collagen 
I (Coll I), α-tubulin, and β-actin with the corresponding 
horseradish peroxidase-conjugated secondary antibodies 
and detected with ECL. Details of the primary antibodies 
used are listed in Table 1.
PAGE zymography
MMP-2 activity was determined by PAGE 
zymography based on prior reports [36]. Cell lysates 
(10μg) were added to nonreducing sample buffer (1:3, 
v/v) and loaded on to Novex 10% zymogram plus 
(gelatin) gels (Thermo Fisher Scientific, Halethorpe, MD); 
electrophoresis was performed at 100 V for ~2 h at 4 °C. 
The gels were then rinsed trice with 2.5% Triton X-100 to 
remove SDS and renature the MMPs in renaturing buffer. 
After a brief wash in distilled water, gels were incubated 
overnight at 37 °C in developing buffer with gentle 
agitation. The gels were stained with Coomassie® Brillant 
Blue R-250 (Sigma), and MMP activities were detected as 
transparent bands on the blue background.
Co-immunoprecipitation
Co-immuno-precipitation was performed as 
described previously [37]. VSMCs from young rat aortae 
were lysed with non-denaturing lysis buffer (20 mM 
Tris HCl, 150 mM NaCl, 10% glycerol, 1% glycerol, 
1% Nonidet P-40, and 2mM EDTA). After that, 100 μl 
of Protein A/G plus bead slurry were added to 400 μg 
of precleared lysate, incubated for 1 hour at 4°C with 
gentle agitation, and then centrifuged at 14,000 x g for 
15 minutes at 4°C. The supernatants were transferred to a 
fresh tube, to which 40 μl of TGF-β1 antibody was added, 
then samples were further incubated at 4°C for 3 hours. 
To each tube, 100 μl of protein A/G plus bead slurry was 
added and incubated at 4°C overnight. The beads were 
collected by centrifugation and washed three times with 
lysis buffer. All supernatant was removed and 50 μl of 
2x Laemmli sample buffer was added before heating at 
95°C for 5 minutes. The samples were separated with 4% 
to 12% NuPAGE gels and immunoblotted with antibodies 
against vasorin and TGF-β1.
Overexpression of vasorin
Overexpression of the vasorin gene was 
accomplished via a transient transfection of rat VSMCs 
with a bicistronic expression vector, pIRES2-DsRed 
(Clontech Laboratories, Inc. CA; Catalog No. 632540), 
containing human vasorin cDNA (HV-cDNA). The HV-
cDNA, containing a C-terminus tag, kindly provided 
by Dr Yuichi Iked (University of Tokyo) was created 
through standard PCR procedures using a recombinant 
adenovirus as a template (Adeno-X system by Clontech). 
The transfection plasmid, IRES-DsRed, was obtained by 
cloning the PCR amplification product into the pIRES2-
DsRed bicistronic expression vector (Clontech, CA) using 
the EcoRI and BamHI sites. The primer sequences used 
to create the PCR fragment with the two restriction sites 
were, 5’-CTGAATTCATGTGCTCCAGGGTCCCT-3’ for 
the forward and 5’-TAGGATCCTCGGATCATCCAGCA
CAGT-3’ for the reverse. The sequences were confirmed, 
and the PCR fragment was cloned into the pIRES2-DsRed 
bicistronic expression vector (Clontech, CA). Plasmid 
transfection of young and old rat VSMCs was achieved 
using the Fugene-HD transfection reagent following 
the manufacturer’s protocol (Roche Diagonostics, 
Mannheim, Germany). After 48 hours, cells were sorted 
with flow cytometric analysis to positively select the red 
fluorescent cells to obtain a pure population (over 90%) of 
overexpressing vasorin cells.
VSMC invasion
Invasion assays were performed on young and 
old VSMCs using a modified Boyden chamber with a 
Matrigel (cat #356234, BD Bioscience-Discovery) coated 
filter (Neuroprobe) as previously described [36]. Young 
VSMCs overexpressing vasorin were treated with or 
without Ang II (100 nmol) for 24 hours. PDGF-BB (10 
ng/ml) served as a chemoattractant control. Addition of 
Matrigel to the filter of the modified Boyden chamber, 
mimics the basement membrane of cells, requiring cells to 
release MMP-2 to degrade the membrane before invading 
through the pore towards the chemoattractant.
Cleavage of the recombinant human vasorin and 
monkey arterial lysate containing vasorin
Vasorin cleavage was performed using a modified 
protocol as previously described [38]. Purified 
recombinant human MMP-2 (R&D Systems), recombinant 
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vasorin (Sino Biological Inc.) and its inhibitor GM 6001 
(abcam), homogenous monkey aortic lysate (grantome.
com/grant/NIH/ZIA-AG000238-05) were dissolved in 50 
mM Tris buffer containing 5mM CaCl2 and 0.2M MgCl2, 
pH 7.5. MMP-2 (50nM) was added to the vasorin (400 
ng/ml)/aortic lysate (25 μg/ml) with or without GM 6001 
(20nM) and incubated in the incubation buffer (pH7.5) 
containing 1% Triton X-100, 50 mM Tris-HCI, 5mM 
CaCI2 1μM ZnCI2 at 37 °C for 24 h. The aliquots (20 μl) 
were withdrawn to 8 μl of 1.0 m EDTA and then mixed 
with the 5x sample buffer (60 mm Tris-HCl, pH 6.8, 
2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% 
bromophenol blue) and subjected to SDS-PAGE followed 
by Western immunoblotting.
Statistical analysis
All experiments were performed in at the least 
three independent experiments and three different rats. 
Data analysis was performed using GraphPad Prism. 
Data were expressed as Mean ± SEM. For two groups, 
comparisons of means were made using Student’s 
unpaired two tailed test (T-test), and for more than two 
groups, comparisons of means were made using one-
way ANOVA with Bonferroni post hoc test. p<0.05 was 
considered as significant level.
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